Critical Survey: XTL Biopharmaceuticals (NASDAQ:XTLB) & BioMarin Pharmaceutical (NASDAQ:BMRN)

XTL Biopharmaceuticals (NASDAQ:XTLB) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Earnings & Valuation

This table compares XTL Biopharmaceuticals and BioMarin Pharmaceutical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450,000.00	9.72	-$6.97 million	($0.64)	-2.88
BioMarin Pharmaceutical	$3.41 billion	3.11	$348.90 million	$0.37	147.78

BioMarin Pharmaceutical has higher revenue and earnings than XTL Biopharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

XTL Biopharmaceuticals has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for XTL Biopharmaceuticals and BioMarin Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1	0	0	0	1.00
BioMarin Pharmaceutical	1	6	14	3	2.79

BioMarin Pharmaceutical has a consensus price target of $88.87, indicating a potential upside of 62.53%. Given BioMarin Pharmaceutical’s stronger consensus rating and higher possible upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than XTL Biopharmaceuticals.

Insider and Institutional Ownership

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. Comparatively, 98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Comparatively, 0.7% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares XTL Biopharmaceuticals and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
BioMarin Pharmaceutical	2.14%	5.32%	3.69%

Summary

BioMarin Pharmaceutical beats XTL Biopharmaceuticals on 12 of the 15 factors compared between the two stocks.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.